Generic placeholder image

Current Molecular Medicine

Author(s): Abdelraouf A. Abonar, Shymaa E. Ayoub*, Ibrahim A. Tagreda, Marwa N. Abdelhafez , Mohammed M. Khamiss, Mohamed I. Abdelaziz, Sylvana N. Gaber, Amal Amin and Shereen R. Mohammed

DOI: 10.2174/1566524021666210225101358

DownloadDownload PDF Flyer Cite As
The Impact of Cell-free Plasma DNA on Metastatic and Nonmetastatic Prostate Cancer

Page: [67 - 73] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Intorductuion: Increased cell-free DNA (cfDNA) is observed in many diseases such as cancer, myocardial infarction, and autoimmune diseases. It has the ability to alter the receptor cell phenotype, triggering events related to malignant transformation.

Aims: Our study aims at assessing the use of cell-free plasma DNA in the diagnosis of metastatic and non-metastatic prostate cancer.

Methods: The study included 180 subjects who were classified into four groups: Group I (GI) included 50 perfect health subjects as the control group, Group II (GII) included 40 patients with prostatitis, group III (GIII) included 40 patients with benign prostatic hyperplasia (BPH) and Group IV (GIV) included 50 patients with pre-operative prostate cancer (PC). Evaluation of the plasma level of circulating cell-free DNA by real-time PCR and measurement of total PSA (tPSA) and free to total PSA percent (f/tPSA%) were carried out for all groups.

Results: Our study revealed that the level of tPSA was significantly higher in prostate cancer patients, while levels of f/t PSA were found to be significantly lower. The level of cfDNA was significantly higher in prostate cancer patients (399.9±88.6ng/ul) when compared to that of group I (12.1±1.5ng/ul) (p<0.01), group II (14.7±2.4 ng/ul) (p<0.01), and group III (26.6±45.6 ng/ul) (p<0.01) respectively.

Conclusion: There was a statistically significant difference in yields of cfDNA between metastatic and non-metastatic groups (P=0.03) with a higher level in the metastatic group.

Keywords: Circulating cell-free DNA, prostate cancer, benign prostate hyperplasia, prostatitis, total PSA, free PSA.

[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Siege L, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016; 66: 7-30.
[3]
Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol 2010; 7(9): 487-93.
[http://dx.doi.org/10.1038/nrurol.2010.120] [PMID: 20818326]
[4]
Porcaro AB, Migliorini F, Romano M, et al. Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients. Int Urol Nephrol 2010; 42(3): 673-81.
[http://dx.doi.org/10.1007/s11255-009-9669-z] [PMID: 19902378]
[5]
Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009; 101(11): 1833-8.
[http://dx.doi.org/10.1038/sj.bjc.6605422] [PMID: 19904272]
[6]
Mouliere F, Robert B, Arnau Peyrotte E, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011; 6(9)e23418
[http://dx.doi.org/10.1371/journal.pone.0023418] [PMID: 21909401]
[7]
Casadio V, Salvi S, Martignano F, Gunelli R, Ravaioli S, Calistri D. Cell-free DNA integrity analysis in urine samples. J Vis Exp 2017; 5(119)
[http://dx.doi.org/10.3791/55049] [PMID: 28117781]
[8]
Stroun M, Anker P. Circulating DNA in higher organisms cancer detection brings back to life an ignored phenomenon. Cell Mol Biol 2005; 51(8): 767-74.
[PMID: 16359626]
[9]
Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004; 22(20): 4157-64.
[http://dx.doi.org/10.1200/JCO.2004.11.123] [PMID: 15483026]
[10]
McGuire AL, Urosevic N, Chan DT, Dogra G, Inglis TJ. The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels. PPAR 2014; p. 643189.
[11]
Batth IS, Mitra A, Manier S, et al. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol 2017; 28(3): 468-77.
[http://dx.doi.org/10.1093/annonc/mdw619] [PMID: 27998963]
[12]
Duffy MJ. PSA in screening for prostate cancer: more good than harm or more harm than good? Adv Clin Chem 2014; 66: 1-23.
[http://dx.doi.org/10.1016/B978-0-12-801401-1.00001-3] [PMID: 25344984]
[13]
Lu JL, Liang ZY. Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns. Chronic Dis Transl Med 2016; 2(4): 223-30.
[http://dx.doi.org/10.1016/j.cdtm.2016.12.001] [PMID: 29063046]
[14]
Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 2010; 10(2): 142-65.
[http://dx.doi.org/10.2174/156652410790963295] [PMID: 20196731]
[15]
Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56(2): 255-60.
[http://dx.doi.org/10.1016/S0090-4295(00)00637-3] [PMID: 10925089]
[16]
Omar J, Jaafar Z, Abdullah MR. A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening. Malays J Med Sci 2009; 16(1): 44-7.
[PMID: 22589648]
[17]
Li J, Gregory SG, Garcia-Blanco MA, Armstrong AJ. Using circulating tumor cells to inform on prostate cancer biology and clinical utility. Crit Rev Clin Lab Sci 2015; 52(4): 191-210.
[http://dx.doi.org/10.3109/10408363.2015.1023430] [PMID: 26079252]
[18]
Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin Chem 2010; 56(8): 1279-86.
[http://dx.doi.org/10.1373/clinchem.2010.144188] [PMID: 20558635]
[19]
Perkins G, Yap TA, Pope L, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012; 7(11)e47020
[http://dx.doi.org/10.1371/journal.pone.0047020] [PMID: 23144797]
[20]
Elnadry M, Alkelany Y F, Amin M. Level of circulating cell-free DNA in the serum of Egyptian patients as a biomarker for diagnosis and prognostic prediction of colorectal cancerEjpmr 2017; 4(5)
[21]
Seyedolmohadessin SM, Akbari MT, Nourmohammadi Z, Basiri A, Pourmand G. Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening. Iran Biomed J 2018; 22(5): 331-7.
[http://dx.doi.org/10.29252/ibj.22.5.331] [PMID: 29475366]
[22]
Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sci 2004; 1022: 76-80.
[http://dx.doi.org/10.1196/annals.1318.013] [PMID: 15251943]
[23]
Gordian E, Ramachandran K, Reis IM, Manoharan M, Soloway MS, Singal R. Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol Biomarkers Prev 2010; 19(8): 1984-91.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0287] [PMID: 20647404]
[24]
Karima M. Sweify, AmalFawzy, Hany M. El-Fayoumy, Nagwa Nofal: Evaluation of cell free circulating plasma DNA in prostate cancer. J Sci Res Sci 2018; 34(1): 108-22.
[http://dx.doi.org/10.21608/jsrs.2018.12760]
[25]
Jung K, Stephan C, Lewandowski M, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett 2004; 205(2): 173-80.
[http://dx.doi.org/10.1016/j.canlet.2003.11.023] [PMID: 15036649]